This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Webinar | English | 24:15

Biologic treatment in severe eosinophilic asthma; what matters most for patients?

Biologic treatment in severe eosinophilic asthma; what matters most for patients?

Using a case study of a patient with severe eosinophilic asthma, the webinar will address:
How can I identify patients with severe asthma who are suitable for biologic therapy?
What are the current treatment options?
Are all biologics the same? Can we differentiate them using their pharmacological properties and clinical efficacy and safety results?


Professor Peter Howarth

Professor Peter Howarth

GSK Global Medical Expert

Professor Peter Howarth has been a part-time Global Medical Expert from 2016 with GSK and continues in a part-time role as Professor of Allergy and Respiratory Medicine in Southampton, UK. Professor Howarth established the severe asthma and clinical allergy services in Southampton, following his appointment as an honorary consultant in 1988, and has long experience of dealing with severe asthma, which is the focus of his current research. He has been involved in EU-funded collaborative asthma and allergy programs, including U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes), which focuses on severe asthma. He co-ordinates the Wessex Severe Asthma Cohort, which is funded by the Medical Research Council in the UK. Professor Howarth has published over 300 peer-reviewed papers (with an H-index of 90) and contributed to National, European and International (World Health Organisation) guidelines on the management of rhinitis and asthma.